Prostaglandin transporter modulates wound healing in diabetes by regulating prostaglandin-induced angiogenesis

American Journal of Pathology

Volumn 181, Issue 1, 2012, Pages 334-346

  Syeda, Mahrukh M ^a   Jing, Xiaohong ^b   Mirza, Raihan H ^a   Yu, Hong ^a   Sellers, Rani S ^a   Chi, Yuling ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID TRANSPORTER; PROSTAGLANDIN E2; PROSTAGLANDIN INHIBITOR; PROSTAGLANDIN TRANSPORTER; T26A; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; EPITHELIZATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VIVO STUDY; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WOUND CLOSURE; WOUND HEALING;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DINOPROSTONE; ENDOTHELIUM, VASCULAR; EPITHELIAL CELLS; HUMANS; HYPERGLYCEMIA; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; ORGANIC ANION TRANSPORTERS; REGIONAL BLOOD FLOW; SKIN; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84862666570     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.03.012     Document Type: Article

References (66)

1. Pecoraro RE, Reiber GE, Burgess EM: Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990, 13:513-521
2. Jeffcoate W, Bakker K: World Diabetes Day: footing the bill. Lancet 2005, 365:1527
3. Cheer K, Shearman C, Jude EB: Managing complications of the diabetic foot. BMJ 2009, 339:b4905
4. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW: Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994, 331:854-860
5. White R, McIntosh C: A review of the literature on topical therapies for diabetic foot ulcers. Part 2: Advanced treatments. J Wound Care 2009, 18:335-341
6. Rissanen TT, Vajanto I, Ylä-Herttuala S: Gene therapy for therapeutic angiogenesis in critically ischemic lower limb - On the way to the clinic. Eur J Clin Invest 2001, 31:651-666
7. Dalla Paola L, Faglia E: Treatment of diabetic foot ulcer: an overview strategies for clinical approach. Curr Diabetes Rev 2006, 2:431-447
8. Frykberg RG: Diabetic foot ulcers: pathogenesis and management. Am Fam Physician 2002, 66:1655-1662
9. Teixeira AS, Andrade SP: Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. Life Sci 1999, 64:655-662
10. Zachary I, Gliki G: Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001, 49:568-581
11. Weeks JR: Prostaglandins. Annu Rev Pharmacol 1972, 12:317-336
12. Neisius U, Olsson R, Rukwied R, Lischetzki G, Schmelz M: Prostaglandin E2 induces vasodilation and pruritus, but no protein extravasation in atopic dermatitis and controls. J Am Acad Dermatol 2002, 47:28-32
13. Carter J, Reynoldson JA, Thorburn GD: The effects of certain vasodilating prostaglandins on the coronary and hindlimb vascular beds of the conscious sheep. Comp Biochem Physiol C: 1986, 83:401-406
14. Holzer P, Jocic M, Peskar BA: Mediation by prostaglandins of the nitric oxide-induced neurogenic vasodilatation in rat skin. Br J Pharmacol 1995, 116:2365-2370
15. Ding YB, Shi RH, Tong JD, Li XY, Zhang GX, Xiao WM, Yang JG, Bao Y, Wu J, Yan ZG, Wang XH: PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system. Exp Oncol 2005, 27:108-113
16. Hatazawa R, Tanaka A, Tanigami M, Amagase K, Kato S, Ashida Y, Takeuchi K: Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. Am J Physiol Gastrointest Liver Physiol 2007, 293:G788-G797
17. Spinella F, Rosanò L, Elia G, Di Castro V, Natali PG, Bagnato A: Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 2004, 279:46700-46705
18. Ben-Av P, Crofford LJ, Wilder RL, Hla T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995, 372:83-87
19. Werner S, Grose R: Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003, 83:835-870
20. Pandya NM, Dhalla NS, Santani DD: Angiogenesis - a new target for future therapy. Vascul Pharmacol 2006, 44:265-274
21. Kämpfer H, Bräutigam L, Geisslinger G, Pfeilschifter J, Frank S: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol 2003, 120:880-890
22. Kämpfer H, Schmidt R, Geisslinger G, Pfeilschifter J, Frank S: Wound inflammation in diabetic ob/ob mice functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 activity in diabetes-impaired wound healing. Diabetes 2005, 54:1543-1551
23. Nomura T, Lu R, Pucci ML, Schuster VL: The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol 2004, 65:973-978
24. Chang HY, Locker J, Lu R, Schuster VL: Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice. Circulation 2010, 121:529-536
25. 2 transport. J Pharmacol Exp Ther 2006, 316:1346-1350
26. Chi Y, Min J, Jasmin JF, Lisanti MP, Chang YT, Schuster VL: Development of a high-affinity inhibitor of prostaglandin transporter. J Pharmacol Exp Ther 2011, 349:633-641
27. Rao R, Redha R, Macias-Perez I, Su Y, Hao C, Zent R, Breyer MD, Pozzi A: Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 2007, 282:16959-16968
28. Nakatsu MN, Davis J, Hughes CC: Optimized fibrin gel bead assay for the study of angiogenesis. J Vis Exp 2007, (3):186
29. Galiano RD, Michaels J 5th, Dobryansky M, Levine JP, Gurtner GC: Quantitative and reproducible murine model of excisional wound healing. Wound Repair Regen 2004, 12:485-492
30. Jain M, LoGerfo FW, Guthrie P, Pradhan L: Effect of hyperglycemia and neuropeptides on interleukin-8 expression and angiogenesis in dermal microvascular endothelial cells. J Vasc Surg 2011, 53:1654-1660.e2
31. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells [Erratum appeared in Cell 1998, 94: following 271]. Cell 1998, 93:705-716
32. Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, Galiano RD, Du XL, Grogan R, Galvez MG, Januszyk M, Brownlee M, Gurtner GC: The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA 2009, 106:13505-13510
33. Ansel JC, Tiesman JP, Olerud JE, Krueger JG, Krane JF, Tara DC, Shipley GD, Gilbertson D, Usui ML, Hart CE: Human keratinocytes are a major source of cutaneous platelet-derived growth factor. J Clin Invest 1993, 92:671-678
34. Scherer SS, Pietramaggiori G, Mathews JC, Orgill DP: Short periodic applications of the vacuum-assisted closure device cause an extended tissue response in the diabetic mouse model. Plast Reconstr Surg 2009, 124:1458-1465
35. Galeano M, Bitto A, Altavilla D, Minutoli L, Polito F, Calò M, Lo Cascio P, Stagno D'Alcontres F, Squadrito F: Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse. Wound Repair Regen 2008, 16:208-217
36. Scherer SS, Pietramaggiori G, Matthews J, Perry S, Assmann A, Carothers A, Demcheva M, Muise-Helmericks RC, Seth A, Vournakis JN, Valeri RC, Fischer TH, Hechtman HB, Orgill DP: Poly-N-acetyl glucosamine nanofibers: a new bioactive material to enhance diabetic wound healing by cell migration and angiogenesis [Erratum appeared in Ann Surg 2009, 250:661]. Ann Surg 2009, 250:322-330
37. Lu R, Schuster VL: Molecular cloning of the gene for the human prostaglandin transporter hPGT: gene organization, promoter activity, and chromosomal localization. Biochem Biophys Res Commun 1998, 246:805-812
38. Pedroso DC, Tellechea A, Moura L, Fidalgo-Carvalho I, Duarte J, Carvalho E, Ferreira L: Improved survival, vascular differentiation and wound healing potential of stem cells co-cultured with endothelial cells. PLoS One 2011, 6:e16114
39. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL: Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 1994, 145:510-514
40. Singer AJ, Clark RA: Cutaneous wound healing. N Engl J Med 1999, 341:738-746
41. Brem H, Jacobs T, Vileikyte L, Weinberger S, Gibber M, Gill K, Tarnovskaya A, Entero H, Boulton AJ: Wound-healing protocols for diabetic foot and pressure ulcers. Surg Technol Int 2003, 11:85-92
42. Blakytny R, Jude EB: Altered molecular mechanisms of diabetic foot ulcers. Int J Low Extrem Wounds 2009, 8:95-104
43. Ansari KM, Rundhaug JE, Fischer SM: Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation. Mol Cancer Res 2008, 6:1003-1016
44. Fukuda R, Kelly B, Semenza GL: Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003, 63:2330-2334
45. Subbaramaiah K, Hudis CA, Dannenberg AJ: The prostaglandin transporter regulates adipogenesis and aromatase transcription. Cancer Prev Res (Phila) 2011, 4:194-206
46. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613
47. Mace KA, Yu DH, Paydar KZ, Boudreau N, Young DM: Sustained expression of Hif-1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair. Wound Repair Regen 2007, 15:636-645
48. Botusan IR, Sunkari VG, Savu O, Catrina AI, Grünler J, Lindberg S, Pereira T, Ylä-Herttuala S, Poellinger L, Brismar K, Catrina SB: Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci USA 2008, 105:19426-19431
49. Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW: EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway. Mol Pharmacol 2010, 77:1025-1036
50. Brem H, Tomic-Canic M: Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007, 117:1219-1222
51. Vane JR: Prostaglandins as mediators of inflammation. Adv Prostaglandin Thromboxane Res 1976, 2:791-801
52. Bonta IL, Parnham MJ: Prostaglandins and chronic inflammation. Biochem Pharmacol 1978, 27:1611-1623
53. Kuehl FA Jr, Egan RW: Prostaglandins, arachidonic acid, and inflammation. Science 1980, 210:978-984
54. Treffkorn L, Scheibe R, Maruyama T, Dieter P: PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha, IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostaglandins Other Lipid Mediat 2004, 74:113-123
55. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001, 2:612-619
56. Su WH, Cheng MH, Lee WL, Tsou TS, Chang WH, Chen CS, Wang PH: Nonsteroidal anti-inflammatory drugs for wounds: pain relief or excessive scar formation? Mediators Inflamm 2010, 2010:413238
57. Liu F, Mih JD, Shea BS, Kho AT, Sharif AS, Tager AM, Tschumperlin DJ: Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 2010, 190:693-706
58. Chi Y, Schuster VL: The prostaglandin transporter PGT transports PGH(2). Biochem Biophys Res Commun 2010, 395:168-172
59. Itoh S, Lu R, Bao Y, Morrow JD, Roberts LJ, Schuster VL: Structural determinants of substrates for the prostaglandin transporter PGT. Mol Pharmacol 1996, 50:738-742
60. Ferreira SH, Vane JR: Prostaglandins: their disappearance from and release into the circulation. Nature 1967, 216:868-873
61. Hamberg M, Samuelsson B: On the catabolism of prostaglandins E 1 and E 2 in man. J Biol Chem 1971, 246:6713-6721
62. Mirenda F, La Spada M, Baccellieri D, Stilo F, Benedetto F, Spinelli F: Iloprost infusion in diabetic patients with peripheral arterial occlusive disease and foot ulcers. Chir Ital 2005, 57:731-735
63. Okuda Y, Sone H, Mizutani S, Asano M, Tsurushima Y, Ogawa M, Tada K, Asakura Y, Kawakami Y, Suzuki S, Yamashita K: Acute effect of beraprost sodium on lower limb circulation in patients with noninsulin-dependent diabetes mellitus-evaluation by color Doppler ultrasonography and laser cutaneous blood flowmetry. Prostaglandins 1996, 52:375-384
64. Ueno Y, Yamada N, Koike H, Nishio S: Effects of beraprost sodium and prostaglandin E1 on skin blood flow in diabetic rats and normal dogs. Gen Pharmacol 1996, 27:333-335
65. Ueno Y, Koike H, Nakamura Y, Ochi Y, Annoh S, Nishio S: Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin-induced diabetic rats. Jpn J Pharmacol 1996, 70:177-182
66. Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, McNamara T, Nehler M; Circulase investigators: Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg 2006, 43:752-759